HIV-1 infection
|
0.050 |
Biomarker
|
disease |
BEFREE |
The CCR3 ligand, eotaxin, and an anti-CCR3 antibody inhibited HIV-1 infection of microglia, as did MIP-1beta, which is a CCR5 ligand.
|
9024664 |
1997 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Unique among known human herpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) encodes chemokine-like proteins (vMIP-I and vMIP-II). vMIP-II was shown to block infection of human immunodeficiency virus-type 1 (HIV-1) on a CD4-positive cell line expressing CCR3 and to a lesser extent on one expressing CCR5, whereas both vMIP-I and vMIP-II partially inhibited HIV infection of peripheral blood mononuclear cells.
|
9323208 |
1997 |
Kaposi Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Like eotaxin, vMIP-II activated and chemoattracted human eosinophils by way of CCR3. vMIP-I and vMIP-II, but not cellular MIP-1alpha or RANTES, were highly angiogenic in the chorioallantoic assay, suggesting a possible pathogenic role in Kaposi's sarcoma.
|
9323208 |
1997 |
Central Nervous System Infection
|
0.010 |
Biomarker
|
group |
BEFREE |
CCR3 appears critical in central nervous system infection.
|
9334732 |
1997 |
Rheumatoid Arthritis
|
0.140 |
Biomarker
|
disease |
BEFREE |
By contrast, CCR3+ T lymphocytes were absent from tissues that lack eosinophils, as demonstrated for normal skin and rheumatoid arthritis synovium.
|
9480044 |
1997 |
HIV-1 infection
|
0.050 |
Biomarker
|
disease |
BEFREE |
Thus, CCR5, not CCR3, is an essential receptor for HIV-1 infection of monocytes.
|
9525662 |
1998 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.040 |
Biomarker
|
disease |
BEFREE |
Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia.
|
9525662 |
1998 |
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The beta chemokines and antibodies to CCR3 failed to affect viral infection of both macrophage cell types.
|
9525662 |
1998 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.040 |
Biomarker
|
disease |
BEFREE |
We have tested a panel of pediatric and adult human immunodeficiency virus type 1 (HIV-1) primary isolates for the ability to employ the following proteins as coreceptors during viral entry: CCR1, CCR2b, CCR3, CCR4, CCR5, CCR8, CXCR4, Bonzo, BOB, GPR1, V28, US28, and APJ.
|
9765485 |
1998 |
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to enumerate CD34(+) cell numbers in blood and bone marrow from atopic asthmatics and control subjects and to test the hypothesis that there is an increased bone marrow pool of CCR3(+) eosinophils in patients with atopic asthma, as compared with control subjects.
|
9893192 |
1999 |
Allergic asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to enumerate CD34(+) cell numbers in blood and bone marrow from atopic asthmatics and control subjects and to test the hypothesis that there is an increased bone marrow pool of CCR3(+) eosinophils in patients with atopic asthma, as compared with control subjects.
|
9893192 |
1999 |
IgE-mediated allergic asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to enumerate CD34(+) cell numbers in blood and bone marrow from atopic asthmatics and control subjects and to test the hypothesis that there is an increased bone marrow pool of CCR3(+) eosinophils in patients with atopic asthma, as compared with control subjects.
|
9893192 |
1999 |
HIV Infections
|
0.320 |
Biomarker
|
group |
CTD_human |
Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy.
|
10202824 |
1999 |
HIV Coinfection
|
0.300 |
Biomarker
|
disease |
CTD_human |
Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy.
|
10202824 |
1999 |
Eosinophilia
|
0.070 |
Biomarker
|
disease |
BEFREE |
Repeated anti-CCR3 mAb treatment in these mice significantly reduced tissue eosinophilia in the lung tissue and bronchoalveolar lavage fluid.
|
10380909 |
1999 |
Eosinophilic disorder
|
0.060 |
Biomarker
|
group |
BEFREE |
Repeated anti-CCR3 mAb treatment in these mice significantly reduced tissue eosinophilia in the lung tissue and bronchoalveolar lavage fluid.
|
10380909 |
1999 |
Nasal Polyps
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, these findings suggested an important role for CCR3-binding chemokines in eosinophil recruitment to nasal polyps.
|
10415058 |
1999 |
Dermatitis, Atopic
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Immunoreactivity and transcripts of eotaxin and CCR3 were significantly increased in lesional skin from atopic dermatitis, but not in nonatopic controls.
|
10417617 |
1999 |
Eczema
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Immunoreactivity and transcripts of eotaxin and CCR3 were significantly increased in lesional skin from atopic dermatitis, but not in nonatopic controls.
|
10417617 |
1999 |
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined the expression of eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), MCP-4, and CCR3 in the bronchial mucosa from atopic (AA) and nonatopic (intrinsic; NAA) asthmatics and compared our findings with atopic (AC) and nonatopic nonasthmatic controls (NC).
|
10570327 |
1999 |
Eosinophilia
|
0.070 |
Biomarker
|
disease |
BEFREE |
These findings suggest that multiple C-C chemokines, acting at least in part via CCR3, contribute to bronchial eosinophilia in both atopic and nonatopic asthma.
|
10570327 |
1999 |
Eosinophilic disorder
|
0.060 |
Biomarker
|
group |
BEFREE |
These findings suggest that multiple C-C chemokines, acting at least in part via CCR3, contribute to bronchial eosinophilia in both atopic and nonatopic asthma.
|
10570327 |
1999 |
Arteriosclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation.
|
11056090 |
2000 |
Atherosclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation.
|
11056090 |
2000 |
Vascular inflammations
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation.
|
11056090 |
2000 |